Chronic Myeloid Leukemia
Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)
A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients.... Continue Reading
People with chronic myeloid leukemia (CML) that is in complete remission after two years of treatment with Gleevec® (imatinib) have survival rates that are similar to those of the general population.... Continue Reading
According to updated results from a Phase III clinical trial, Tasigna® (nilotinib) continues to be more effective than Gleevec® (imatinib) for the initial treatment of adult patients with newly diagnosed... Continue Reading
The U.S. Food and Drug Administration has expanded the approval of Sprycel® (dasatinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic... Continue Reading
The U.S. Food and Drug Administration has expanded the approval of Tasigna® (nilotinib) to include the initial treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic... Continue Reading
In the initial treatment of chronic myeloid leukemia (CML), Sprycel® (dasatinib) produces higher response rates than Gleevec® (imatinib). These results were presented at the 2010 annual meeting of the... Continue Reading
Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according... Continue Reading
For leukemia patients who undergo allogeneic stem cell transplantation, 10-year results indicate that bone-marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) produce similar... Continue Reading
In the initial treatment of chronic myeloid leukemia (CML), Tasigna® (nilotinib) appears to produce higher response rates than Gleevec® (imatinib) 400 mg/day. These results were presented at the 2009... Continue Reading
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment... Continue Reading
